특허 제40-2171071호_CTSoln
페이지 정보
본문
제40-2171071호_CTSoln
- 이전글
2024, NPJ Precision Oncology, Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion 24.05.22 - 다음글
2024, Advanced Therapeutics, A Feasibility Test of the Disposable Drug Daughter Plate Combined with 384-Pillar Plate for Patient-Derived Organoid-Based High Throughput Screening 24.03.19
